Amylyx Pharmaceuticals, Inc. ("Amylyx" or the "Company") today announced the pricing of an underwritten public offering of 17,142,857 shares of its common stock at a public offering price of $3.50 per ...
Researchers have developed a therapy to treat Stargardt disease, the most common form of inherited macular degeneration, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback